Evidence map›Paper›PMID 27462916›Full record

ArticleOncotarget2016

p53 elevation in human cells halt SV40 infection by inhibiting T-ag expression.

Nir Drayman, Orly Ben-Nun-Shaul, Veronika Butin-Israeli, Rohit Srivastava, Ariel M Rubinstein, Caroline S Mock, Ela Elyada, Yinon Ben-Neriah, Galit Lahav, Ariella Oppenheim

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Downregulation of miR‑7 and miR‑153 is involved inInternational journal of oncology · 2023
    Article
  3. The Wheel of p53 Helps to Drive the Immune System.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Sepsis reveals compartment-specific responses in intestinal proliferation and apoptosis in transgenic mice whose enterocytes re-enter the cell cycle.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Nir DraymanDepartment of Hematology, Hebrew University Faculty of Medicine and Hadassah University Hospital, Jerusalem, Israel.
Orly Ben-Nun-ShaulDepartment of Hematology, Hebrew University Faculty of Medicine and Hadassah University Hospital, Jerusalem, Israel.
Veronika Butin-IsraeliDepartment of Hematology, Hebrew University Faculty of Medicine and Hadassah University Hospital, Jerusalem, Israel.
Rohit SrivastavaDepartment of Hematology, Hebrew University Faculty of Medicine and Hadassah University Hospital, Jerusalem, Israel.
Ariel M RubinsteinDepartment of Hematology, Hebrew University Faculty of Medicine and Hadassah University Hospital, Jerusalem, Israel.
Caroline S MockDepartment of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA.
Ela ElyadaThe Lautenberg Center for Immunology and Cancer Research, Hebrew University Faculty of Medicine, Jerusalem, Israel.
Yinon Ben-NeriahThe Lautenberg Center for Immunology and Cancer Research, Hebrew University Faculty of Medicine, Jerusalem, Israel.
Galit LahavDepartment of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA.
Ariella OppenheimDepartment of Hematology, Hebrew University Faculty of Medicine and Hadassah University Hospital, Jerusalem, Israel.
Hebrew University of Jerusalem · ILCenter for Systems Biology · USHarvard University · US

Funding

Dynamics of Signaling Pathways: Mechanism and FunctionR01GM083303 · NIGMS · HARVARD MEDICAL SCHOOL · PI LAHAV, GALIT · 2008 to 2020
$5.2M
NIGMS NIH HHS R01 GM083303
6 · The paper itself

Abstract

SV40 large T-antigen (T-ag) has been known for decades to inactivate the tumor suppressor p53 by sequestration and additional mechanisms. Our present study revealed that the struggle between p53 and T-ag begins very early in the infection cycle. We found that p53 is activated early after SV40 infection and defends the host against the infection. Using live cell imaging and single cell analyses we found that p53 dynamics are variable among individual cells, with only a subset of cells activating p53 immediately after SV40 infection. This cell-to-cell variabilty had clear consequences on the outcome of the infection. None of the cells with elevated p53 at the beginning of the infection proceeded to express T-ag, suggesting a p53-dependent decision between abortive and productive infection. In addition, we show that artificial elevation of p53 levels prior to the infection reduces infection efficiency, supporting a role for p53 in defending against SV40. We further found that the p53-mediated host defense mechanism against SV40 is not facilitated by apoptosis nor via interferon-stimulated genes. Instead p53 binds to the viral DNA at the T-ag promoter region, prevents its transcriptional activation by Sp1, and halts the progress of the infection. These findings shed new light on the long studied struggle between SV40 T-ag and p53, as developed during virus-host coevolution. Our studies indicate that the fate of SV40 infection is determined as soon as the viral DNA enters the nucleus, before the onset of viral gene expression.

Indexed as

Gene Expression Regulation, ViralAnimalsAntigens, Polyomavirus TransformingBreast NeoplasmsCell LineGene Expression Regulation, NeoplasticHost-Pathogen InteractionsHumansMCF-7 CellsMicroscopy, ConfocalPromoter Regions, GeneticProtein BindingSimian virus 40Sp1 Transcription FactorTime-Lapse ImagingTumor Suppressor Protein p53Antigens, Polyomavirus TransformingSp1 Transcription FactorTumor Suppressor Protein p53host defenselarge T-antigenp53Sp1SV40

Identifiers

PMID27462916
PMCPMC5288138
OpenAlexW2486499002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.